The ₹3,395 crore IPO of the Bengaluru-based Anthem Biosciences Ltd (ABL) will open to the public today and close on July 16. The price band has been set at ₹540-570 per share. The market lot is 26 shares.
The issue is entirely an offer-for-sale (OFS) by promoters Ganesh Sambasivam and K Ravindra Chandrappa; investor shareholders Viridity Tone LLP and Portsmouth Technologies LLC; and other shareholders such as Malay J Barua, Rupesh N Kinekar, Satish Sharma, Prakash Kariabettan, and K Ramakrishnan.
The IPO has 35 per cent reservation for retail investors, 50 per cent for QIBs and 15 per cent for HNIs.
ABL is an innovation-driven and technology-focused CRDMO with fully integrated operations in Bengaluru, spanning across drug discovery, development and manufacturing. ABL has a unique model of integrated new chemical entity (NCE) and new biological entity (NBE) capabilities across drug discovery, development and commercial manufacturing, serving a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. ABL is one of the youngest and fastest Indian CRDMO companies to achieve a milestone of ₹1,000 crore in revenue within 14 years of operations.
Anthem Biosciences has raised ₹1,016 crore from anchor investors ahead of its initial share-sale opening for public subscription.
Some of the investors that participated in the anchor book are Abu Dhabi Investment Authority, Government Pension Fund Global, Eastspring Investments, Amundi Funds, PineBridge Global Funds and Societe Generale, HDFC MF (MF), ICICI Prudential MF, Axis MF, UTI MF, Quant MF and Motilal Oswal MF, according to a circular uploaded on BSE’s website late night on Friday. As per the circular, the company has allocated 1.78 crore equity shares to 60 funds at ₹570 apiece.
Anthem is a innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing.
It also manufactures and sells complex specialised fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars.
Sai Life Sciences Ltd, Syngene International, Suven Life Sciences and Divi’s Laboratories are the listed peers of Anthem Biosciences.
JM Financial, Citigroup Global Markets India, J P Morgan India and Nomura Financial Advisory and Securities (India) are the book-running lead managers for the issue.
Published on July 14, 2025
